Projects & Grants
| Life style, quality of life and compliance of patients taking anticoagulants - pilot study | |
|---|---|
| Project Id | SGS10/LF/2019 |
| Main solver | Mgr. Anna Zatloukalová, Ph.D. |
| Period | 1/2019 - 12/2019 |
| Provider | Specifický VŠ výzkum |
| State | finished |
| Anotation | Anticoagulants are drugs that interfere with the coagulation cascade by reducing coagulation. They are used for the treatment and also for prophylaxis of the thrombophilic conditions. Historically, the most commonly used anticoagulant is warfarin. Due to numerous undesirable effects, the need for regular monitoring, drug and food interactions, new direct oral anticoagulants have been developed. These are direct factor IIa (thrombin) inhibitors and direct factor Xa inhibitors. Based on large clinical trials, the following substances were sequentially registered: dabigatran, rivaroxaban, apixaban and edoxaban. These new anticoagulants show comparable or better efficacy compared to warfarin. Their use is also associated with a higher safety profile, for example with a lower risk of clinically significant bleeding, especially intracranial. There is also no need for regular monitoring, which is particularly appreciated by patients themselves. In spite of its numerous benefits, this new anticoagulant has to be monitored epidemiologically and to find valuable information about its lifestyle, quality of life and compliance for its users, which is the task of this pilot study. Information will be gathered through a questionnaire survey on lifestyle, quality of life and compliance. The questionnaires will be distributed by the medical staff of a network of cardiology outpatients. The selection criteria will be warfarin, dabigatran, rivaroxaban or apixaban. |
